Outset Medical (OM) 10-Q 2 Aug 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Jul. 27, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Entity File Number	001-39513
Entity Registrant Name	Outset Medical, Inc.
Entity Central Index Key	0001484612
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-0514392
Entity Address, Address Line One	3052 Orchard Dr.
Entity Address, City or Town	San Jose
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95134
City Area Code	669
Local Phone Number	231-8200
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	OM
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		48,007,301

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 75,497	$ 182,348
Short-term investments	186,565	157,140
Accounts receivable, net	24,627	25,600
Inventories	53,689	39,185
Prepaid expenses and other current assets	5,399	5,529
Total current assets	345,777	409,802
Restricted cash	33,311	33,311
Property and equipment, net	15,245	12,964
Operating lease right-of-use assets	6,687	7,231
Other assets	216	156
Total assets	401,236	463,464
Current liabilities:
Accounts payable	2,753	1,763
Accrued compensation and related benefits	15,795	24,948
Accrued expenses and other current liabilities	23,261	13,789
Accrued warranty liability	3,444	3,704
Deferred revenue, current	7,752	6,340
Operating lease liabilities, current	1,235	1,151
Term loan, current	1,000	0
Total current liabilities	55,240	51,695
Accrued interest, noncurrent	960	721
Deferred revenue, noncurrent	205	312
Operating lease liabilities, noncurrent	6,261	6,893
Term loan, noncurrent	28,806	29,762
Total liabilities	91,472	89,383
Commitments and contingencies (Note 6)
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of June 30, 2022 and December 31, 2021	0	0
Common stock, $0.001 par value; 300,000 shares authorized as of June 30, 2022 and December 31, 2021; 47,997 and 47,241 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	48	47
Additional paid-in capital	1,017,396	1,000,212
Accumulated other comprehensive (loss) income	(955)	(184)
Accumulated deficit	(706,725)	(625,994)
Total stockholders' equity	309,764	374,081
Total liabilities and stockholders' equity	$ 401,236	$ 463,464

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	47,997,000	47,241,000
Common stock, shares outstanding	47,997,000	47,241,000

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue:
Revenue	$ 25,057	$ 25,216	$ 55,607	$ 48,132
Cost of revenue:
Cost of revenue	21,275	24,164	47,383	46,791
Gross profit	3,782	1,052	8,224	1,341
Operating expenses:
Research and development	13,521	8,032	24,352	15,602
Sales and marketing	23,198	13,204	43,575	26,353
General and administrative	10,784	9,722	20,493	18,968
Total operating expenses	47,503	30,958	88,420	60,923
Loss from operations	(43,721)	(29,906)	(80,196)	(59,582)
Interest income and other income, net	459	164	579	276
Interest expense	(481)	(431)	(903)	(853)
Loss before provision for income taxes	(43,743)	(30,173)	(80,520)	(60,159)
Provision for income taxes	96	35	211	74
Net loss	$ (43,839)	$ (30,208)	$ (80,731)	$ (60,233)
Net loss per share, basic and diluted	$ (0.92)	$ (0.66)	$ (1.69)	$ (1.36)
Net loss per share, basic and diluted	$ (0.92)	$ (0.66)	$ (1.69)	$ (1.36)
Shares used in computing net loss per share, basic and diluted	47,882	45,680	47,686	44,228
Shares used in computing net loss per share, basic and diluted	47,882	45,680	47,686	44,228
Product Revenue
Revenue:
Revenue	$ 19,621	$ 20,628	$ 45,285	$ 38,838
Cost of revenue:
Cost of revenue	17,718	22,077	40,828	42,654
Service and Other Revenue
Revenue:
Revenue	5,436	4,588	10,322	9,294
Cost of revenue:
Cost of revenue	$ 3,557	$ 2,087	$ 6,555	$ 4,137

Condensed Statements of Compreh

Condensed Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (43,839)	$ (30,208)	$ (80,731)	$ (60,233)
Other comprehensive loss:
Unrealized loss on available-for-sale securities	(306)	(20)	(771)	(29)
Comprehensive loss	$ (44,145)	$ (30,228)	$ (81,502)	$ (60,262)

Condensed Statement of Redeemab

Condensed Statement of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning Balance at Dec. 31, 2020	$ 328,609	$ 43	$ 822,624	$ 1	$ (494,059)
Beginning Balance (shares) at Dec. 31, 2020		42,722
Issuance of common stock through employee stock purchase plan	1,838		1,838
Issuance of common stock through employee stock purchase plan (shares)		80
Stock option exercises	380		380
Stock option exercises (shares)		86
Stock-based compensation expense	5,852		5,852
Unrealized loss on available-for-sale securities	(9)			(9)
Net loss	(30,025)				(30,025)
Ending Balance at Mar. 31, 2021	306,645	$ 43	830,694	(8)	(524,084)
Ending Balance (shares) at Mar. 31, 2021		42,888
Beginning Balance at Dec. 31, 2020	328,609	$ 43	822,624	1	(494,059)
Beginning Balance (shares) at Dec. 31, 2020		42,722
Unrealized loss on available-for-sale securities	(29)
Net loss	(60,233)
Ending Balance at Jun. 30, 2021	431,162	$ 46	985,436	(28)	(554,292)
Ending Balance (shares) at Jun. 30, 2021		46,225
Beginning Balance at Mar. 31, 2021	306,645	$ 43	830,694	(8)	(524,084)
Beginning Balance (shares) at Mar. 31, 2021		42,888
Issuance of common stock upon initial public offering, net of issuance costs	149,085	$ 3	149,082
Issuance of common stock upon initial public offering, net of issuance costs (shares)		2,946
Issuance of common stock for settlement of RSUs (shares)		1
Stock option exercises	1,723		1,723
Stock option exercises (shares)		390
Stock-based compensation expense	3,937		3,937
Unrealized loss on available-for-sale securities	(20)			(20)
Net loss	(30,208)				(30,208)
Ending Balance at Jun. 30, 2021	431,162	$ 46	985,436	(28)	(554,292)
Ending Balance (shares) at Jun. 30, 2021		46,225
Beginning Balance at Dec. 31, 2021	374,081	$ 47	1,000,212	(184)	(625,994)
Beginning Balance (shares) at Dec. 31, 2021		47,241
Issuance of common stock through employee stock purchase plan	2,063		2,063
Issuance of common stock through employee stock purchase plan (shares)		55
Issuance of common stock for settlement of RSUs (shares)		88
Stock option exercises	1,660	$ 1	1,659
Stock option exercises (shares)		328
Stock-based compensation expense	5,006		5,006
Unrealized loss on available-for-sale securities	(465)			(465)
Net loss	(36,892)				(36,892)
Ending Balance at Mar. 31, 2022	345,453	$ 48	1,008,940	(649)	(662,886)
Ending Balance (shares) at Mar. 31, 2022		47,712
Beginning Balance at Dec. 31, 2021	374,081	$ 47	1,000,212	(184)	(625,994)
Beginning Balance (shares) at Dec. 31, 2021		47,241
Unrealized loss on available-for-sale securities	(771)
Net loss	(80,731)
Ending Balance at Jun. 30, 2022	309,764	$ 48	1,017,396	(955)	(706,725)
Ending Balance (shares) at Jun. 30, 2022		47,997
Beginning Balance at Mar. 31, 2022	345,453	$ 48	1,008,940	(649)	(662,886)
Beginning Balance (shares) at Mar. 31, 2022		47,712
Issuance of common stock for settlement of RSUs	1,042		1,042
Issuance of common stock for settlement of RSUs (shares)		52
Stock option exercises (shares)		233
Stock-based compensation expense	7,414		7,414
Unrealized loss on available-for-sale securities	(306)			(306)
Net loss	(43,839)				(43,839)
Ending Balance at Jun. 30, 2022	$ 309,764	$ 48	$ 1,017,396	$ (955)	$ (706,725)
Ending Balance (shares) at Jun. 30, 2022		47,997

Condensed Statement of Cash Flo

Condensed Statement of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (80,731)	$ (60,233)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	12,420	9,789
Depreciation and amortization	2,586	2,553
Non-cash lease expense	544	501
Non-cash interest expense	282	282
Accretion of discount on investments, net	1,035	435
Provision for inventories	808	325
Other non-cash items	29	5
Changes in operating assets and liabilities:
Accounts receivable	964	(9,946)
Inventories	(15,311)	(12,116)
Prepaid expenses and other assets	70	570
Accounts payable	684	(2,509)
Accrued payroll and related benefits	(9,153)	(1,538)
Accrued expenses and other current liabilities	8,366	1,508
Accrued warranty liability	(260)	160
Deferred revenue	1,305	1,117
Operating lease liabilities	(548)	(360)
Net cash used in operating activities	(76,910)	(69,457)
Cash flows from investing activities:
Purchases of property and equipment	(3,475)	(1,766)
Purchases of investment securities	(133,015)	(122,401)
Sales and maturities of investment securities	101,784	19,900
Net cash used in investing activities	(34,706)	(104,267)
Cash flows from financing activities:
Proceeds from stock option exercises and employee stock purchase plan purchases	4,765	3,941
Proceeds from issuance of common stock upon follow-on public offering, net of issuance costs	0	149,085
Net cash provided by financing activities	4,765	153,026
Net decrease in cash, cash equivalents and restricted cash	(106,851)	(20,698)
Cash, cash equivalents and restricted cash as of beginning of period	215,659	328,283
Cash, cash equivalents and restricted cash as of end of period	108,808	307,585
Supplemental cash flow disclosures:
Cash paid for income taxes	283	42
Cash paid for interest	621	149
Cash paid for amounts included in the measurement of operating lease liabilities	548	360
Supplemental non-cash investing and financing activities:
Capital expenditures included in accounts payable and accrued expenses	1,613	92
Transfer of inventories to property and equipment	$ 0	$ 1,294

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	1. Description of Business Outset Medical, Inc. (the Company) is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hemodialysis System (Tablo), cleared by the U.S. Food and Drug Administration (FDA) for use from the hospital to the home, represents a significant technological advancement designed to transform the dialysis experience for patients and operationally simplify it for providers. Tablo serves as a single enterprise solution designed to be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. The integration of water purification and on-demand dialysate production in a single 35-inch compact console enables Tablo to serve as a dialysis clinic on wheels. With a simple-to-use touchscreen interface, two-way wireless data transmission and a proprietary data analytics platform, Tablo is a new holistic approach to dialysis care. The Company’s headquarters are located in San Jose, CA. Liquidity Since inception, the Company has incurred net losses and negative cash flows from operations. During the six months ended June 30, 2022 and 2021, the Company incurred a net loss of $ 80.7 million and $ 60.2 million , respectively. As of June 30, 2022, the Company had an accumulated deficit of $ 706.7 million . As of June 30, 2022, the Company had cash, cash equivalents and short-term investments of $ 262.1 million , which are available to fund future operations, and restricted cash of $ 33.3 million , for a total cash, cash equivalents, restricted cash and short-term investments balance of $ 295.4 million . Management expects to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while the Company makes investments to support its anticipated growth. Management believes that the Company’s existing cash, cash equivalents, short-term investments and cash generated from sales, will be sufficient to meet its anticipated needs for at least the next 12 months from the issuance date of the accompanying condensed financial statements. Basis of Presentation The accompanying condensed financial statements are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, that are necessary for the fair statement of the Company’s financial position, results of operations, comprehensive loss, and cash flows for the interim periods presented. The financial data and the other financial information disclosed in these notes to the condensed financial statements related to the three- and six-month periods are also unaudited. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the results of operations to be anticipated for any other future annual or interim period. The condensed balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date. These unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2021, which are included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the Securities and Exchange Commission (SEC) on February 23, 2022 (2021 Annual Report). All share amounts disclosed in the notes to the condensed financial statements are rounded to the nearest thousand except for per share data.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies During the six months ended June 30, 2022, there have been no material changes to the Company’s significant accounting policies as described in its 2021 Annual Report that have had a material impact on the Company’s condensed financial statements and related notes. Recently Issued Accounting Pronouncements Not Yet Adopted In June 2016, the Financial Accounting Standards Board (FASB) issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which requires an entity to utilize a new impairment model known as the current expected credit loss (CECL) model to estimate its lifetime “expected credit loss” and record an allowance that, when deducted from the amortized cost basis of the financial assets and certain other instruments, including but not limited to available-for-sale debt securities. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. ASU 2016-13 requires a cumulative effect adjustment to the balance sheet as of the beginning of the first reporting period in which the guidance is effective. In November 2019, the FASB issued ASU 2019-10, Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates , which defers the effective date of ASU 2016-13 to fiscal years beginning after December 15, 2022 for all entities except SEC reporting companies that are not smaller reporting companies. ASU 2016-13 will be effective for the Company beginning January 1, 2023 . The Company is currently evaluating the impact of the adoption of ASU 2016-13 on its financial statements.

Revenue and Deferred Revenue

Revenue and Deferred Revenue	6 Months Ended
	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue and Deferred Revenue	3. Revenue and Deferred Revenue Disaggregation of Revenue Revenue by source consists of the following (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Consoles $ 13,228 $ 16,857 $ 31,279 $ 31,623 Consumables 6,393 3,771 14,006 7,215 Total product revenue 19,621 20,628 45,285 38,838 Service and other revenue 5,436 4,588 10,322 9,294 Total revenue $ 25,057 $ 25,216 $ 55,607 $ 48,132 For the three and six months ended June 30, 2022, $ 0.7 million and $ 1.4 million of consoles revenue were from console operating lease arrangements, compared to $ 1.3 million and $ 2.6 million for the three and six months ended June 30, 2021. Remaining Performance Obligations and Contract Liabilities As of June 30, 2022, the aggregate amount of the transaction price allocated to the remaining performance obligations related to customer service contracts that are unsatisfied or partially unsatisfied was $ 8.0 million , which is recorded as deferred revenue on the Company’s condensed balance sheets. Of that amount, $ 7.8 million will be recognized as revenue during the next 12 months and $ 0.2 million thereafter. The contract liabilities consist of deferred revenue which represents payments received in advance of revenue recognition. Revenue under these agreements is recognized over the related service period. During the three and six months ended June 30, 2022, the Company recognized $ 1.7 m illion and $ 4.2 million of previously deferred revenue.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following tables summarize the Company’s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): June 30, 2022 Valuation Amortized Gross Gross Aggregate Assets: Cash equivalents: Money market funds Level 1 $ 31,353 $ — $ — $ 31,353 Short-term investments: U.S. Treasury securities Level 1 76,950 — ( 518 ) 76,432 Corporate debt Level 2 78,645 — ( 437 ) 78,208 Commercial paper Level 2 31,925 — — 31,925 Total cash equivalents and $ 218,873 $ — $ ( 955 ) $ 217,918 December 31, 2021 Valuation Amortized Gross Gross Aggregate Assets: Cash equivalents: Money market funds Level 1 $ 60,844 $ — $ — $ 60,844 Short-term investments: U.S. Treasury securities Level 1 18,064 — ( 60 ) 18,004 Corporate debt Level 2 124,178 2 ( 125 ) 124,055 Commercial paper Level 2 15,081 — — 15,081 Total cash equivalents and $ 218,167 $ 2 $ ( 185 ) $ 217,984 As of June 30, 2022 , the remaining contractual maturities for available-for-sale securities were one month to thirteen months . Impairment assessments are made at the individual security level at each reporting period. When the fair value of an available-for-sale security is less than its cost at the balance sheet date, a determination is made as to whether the impairment is other-than-temporary and, if it is other-than-temporary, an impairment loss is recognized in earnings equal to the difference between the investment’s amortized cost and fair value at such date. As of June 30, 2022 , there were three securities with a total fair value of $ 18.0 million in an unrealized loss position for more than 12 months. The unrealized losses totaling $ 89,000 as of June 30, 2022 were caused by changes in market interest rates or the widening of market spreads subsequent to the initial purchase of these securities, and not related to the underlying credit of the issuers or the underlying collateral. These securities were issued by public reporting companies with an investment-grade rating by at least one bond credit rating agency. As a result, the Company did not consider these investments to be other-than-temporarily impaired as of June 30, 2022. During the three and six months ended June 30, 2022 and 2021 , the Company did no t recognize other-than-temporary impairment losses related to its investment securities.

Balance Sheet Components

Balance Sheet Components	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	5. Balance Sheet Components As of June 30, 2022 and December 31, 2021, the restricted cash balance of $ 33.3 million primarily relates to contractual obligations under the SVB Loan and Security Agreement (see Note 7) and collateral for building leases in San Jose, CA and Tijuana Mexico. The following table provides a reconciliation of cash, cash equivalents and restricted cash that sum to the total of the amounts shown in the accompanying condensed statements of cash flows (in thousands): June 30, 2022 2021 Cash and cash equivalents $ 75,497 $ 274,274 Restricted cash 33,311 33,311 Total cash, cash equivalents and restricted cash $ 108,808 $ 307,585 Inventories Inventories consist of the following (in thousands): June 30, December 31, 2022 2021 Raw materials $ 20,731 $ 18,114 Work in process 9,434 6,054 Finished goods 23,524 15,017 Total inventories $ 53,689 $ 39,185 Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following (in thousands): June 30, December 31, 2022 2021 Accrued inventory $ 9,904 $ 4,808 Accrued research and development expenses 1,113 574 Accrued professional services 1,745 1,269 Accrued rebate 3,737 3,121 Other 6,762 4,017 Total accrued expenses and other current liabilities $ 23,261 $ 13,789

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	6. Commitments and Contingencies Litigation On July 8, 2022, a purported stockholder class action lawsuit was filed in the U.S. District Court for the Northern District of California, naming the Company, its Chief Executive Officer, Chief Financial Officer, and former Chief Financial Officer as defendants. The complaint alleges that between September 15, 2020 and June 13, 2022, the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (Exchange Act) by making false or misleading statements regarding the Company’s regulatory studies of the Tablo Hemodialysis System for at home use and the Company’s prospects related to the sale of the system for at home use. The Company intends to vigorously defend against this litigation. The case is at a very early stage and there can be no assurance that the Company will be successful in its defense. For this same reason, the Company cannot currently estimate the loss or the range of possible losses it may experience in connection with this litigation. In addition, from time to time, the Company may become involved in other legal proceedings or investigations, which could have an adverse impact on its reputation, business and financial condition and divert the attention of the Company’s management from the operation of the Company’s business. Indemnification In the ordinary course of business, the Company often includes standard indemnification provisions in its arrangements with its partners, customers and suppliers. Pursuant to these provisions, the Company may be obligated to indemnify such parties for losses or claims suffered or incurred in connection with its service, breach of representations or covenants, intellectual property infringement or other claims made against such parties. These provisions may limit the time within which an indemnification claim can be made. It is not possible to determine the maximum potential amount under these indemnification obligations due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. To date, the Company has not incurred any material costs as a result of such indemnification obligations and has not accrued any liabilities related to such obligations in these financial statements.

Term Loan

Term Loan	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Term Loan	7. Term Loan Term loan consists of the following (in thousands): June 30, December 31, 2022 2021 Principal of term loan $ 30,000 $ 30,000 Unamortized debt discount ( 194 ) ( 238 ) Term loan, current and noncurrent 29,806 29,762 Less: term loan, current ( 1,000 ) — Total term loan, noncurrent $ 28,806 $ 29,762 SVB Loan and Security Agreement On July 2, 2020, the Company entered into a senior secured term loan facility with Silicon Valley Bank (SVB) (the SVB Loan and Security Agreement), which provides for a $ 30.0 million term loan (the SVB Term Loan). The SVB Term Loan matures on November 1, 2025 . Payments under the SVB Term Loan are for interest only through May 2023 , and then 30 monthly principal and interest payments from June 2023 until maturity. The SVB Term Loan bears interest at the greater of (A) 0.5 % above the Prime Rate as reported in the Wall Street Journal and (B) 3.75% ( 5.25 % as of June 30, 2022 ). The Company is obligated to maintain a restricted cash balance greater or equal to the outstanding principal balance of $ 30.0 million of the SVB Term Loan.

Equity Incentive Plan

Equity Incentive Plan	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Equity Incentive Plan	8. Equity Incentive Plan Equity Incentive Plans On January 1, 2022, the number of shares of common stock reserved for the issuance of awards under the Company’s 2020 Equity Incentive Plan (the 2020 Plan) was increased by 1,890,000 shares as a result of the automatic increase pursuant to the 2020 Plan. As of June 30, 2022, 5,022,000 shares were reserved for future issuance under the 2020 Plan. Employees Share Purchase Plan (ESPP) On January 1, 2022, the number of shares of common stock reserved for purchase under the Company’s ESPP was increased by 472,000 shares as a result of the automatic increase pursuant to the ESPP. As of June 30, 2022, 1,416,000 shares of common stock were reserved for issuance in connection with the current and future offering periods under the ESPP. Restricted Stock The Company issues restricted stock units (RSUs) and performance stock units (PSUs), both of which are considered restricted stock. The Company grants restricted stock pursuant to the 2020 Plan and satisfies such grants through the issuance of new shares. RSUs are share awards that, upon vesting, will deliver to the holder shares of our common stock. RSUs with a service-based vesting condition granted to a grantee, beginning in February 2022, generally vest over a three-year period as follows either: (i) 25 % on the first anniversary of the original vesting date, 25% quarterly over the course of the second year, and 50% quarterly over the course of the third year, or (ii) 33% on the first anniversary of the original vesting date, with the balance vesting quarterly over the remaining two years. Prior to February 2022, RSUs with a service-based vesting condition granted to a grantee generally vest at a rate of 25% on the first anniversary of the original vesting date , with the balance vesting quarterly over the remaining three years. In 2022, the Company issued a mix of 50 % PSUs and 50 % RSUs to its CEO, and a mix of 20 % PSUs and 80 % RSUs to its other executive officers and certain other senior leaders. These PSUs are earned and vest over performance and vesting periods extending through 2024 based on achievement against two metrics: (1) an operational metric tied to the number of patients treating at home on Tablo as of the end of 2023, with 50 % of earned units vesting after certification of the achievement level following the end of 2023 and the remaining 50 % of earned units vesting at the end of 2024 (performance-based vesting conditions, referred to as the Home PSUs) and (2) the Company's relative total stockholder return (relative TSR) over a two-year performance period as compared to companies in a pre-determined index of medical device companies, with 100% of earned units vesting at the end of 2024 (market-based vesting conditions, referred to as the Relative TSR PSUs). The 2023 target for the Home PSUs is expected to be determined and approved by the Compensation Committee in late 2022 or early 2023. Given such target has not yet been established, the grant date for these Home PSUs will only be established when the Compensation Committee approves and the Company communicates the target to the award recipients, which will then trigger the service inception date, the fair value of the awards, and the associated expense recognition period. Therefore, no expense is expected to be recognized for these Home PSUs until the grant date is established. Stock-Based Compensation Expense The following table sets forth stock-based compensation expense included in the accompanying condensed statements of operations (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Cost of revenue $ 190 $ 62 $ 283 $ 137 Research and development 1,808 643 2,966 1,808 Sales and marketing 2,864 1,052 4,570 2,794 General and administrative 2,552 2,180 4,601 5,050 Total stock-based compensation expense $ 7,414 $ 3,937 $ 12,420 $ 9,789

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes For each of the three and six months ended June 30, 2022 and 2021 , the Company incurred an income tax provision of an insignificant amount, which related to foreign income taxes. The U.S. federal and state net deferred tax assets have been fully offset by a valuation allowance, as the Company believes it is not more likely than not that the deferred tax assets will be realized.

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	10. Net Loss Per Share The following outstanding potentially dilutive shares were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Stock options to purchase common stock 2,900 4,653 2,900 4,653 Restricted stock units 1,513 473 1,513 473 Performance stock units 31 — 31 — Shares committed under ESPP 101 27 101 27 Warrant to purchase common stock 63 63 63 63 Total 4,608 5,216 4,608 5,216

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Event	11. Subsequent Event On July 8, 2022, a purported stockholder class action lawsuit was filed against the Company, certain of its officers and a former officer (see Note 6).

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted In June 2016, the Financial Accounting Standards Board (FASB) issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which requires an entity to utilize a new impairment model known as the current expected credit loss (CECL) model to estimate its lifetime “expected credit loss” and record an allowance that, when deducted from the amortized cost basis of the financial assets and certain other instruments, including but not limited to available-for-sale debt securities. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. ASU 2016-13 requires a cumulative effect adjustment to the balance sheet as of the beginning of the first reporting period in which the guidance is effective. In November 2019, the FASB issued ASU 2019-10, Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates , which defers the effective date of ASU 2016-13 to fiscal years beginning after December 15, 2022 for all entities except SEC reporting companies that are not smaller reporting companies. ASU 2016-13 will be effective for the Company beginning January 1, 2023 . The Company is currently evaluating the impact of the adoption of ASU 2016-13 on its financial statements.

Revenue and Deferred Revenue (T

Revenue and Deferred Revenue (Tables)	6 Months Ended
	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Summary of Revenue by Source	Revenue by source consists of the following (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Consoles $ 13,228 $ 16,857 $ 31,279 $ 31,623 Consumables 6,393 3,771 14,006 7,215 Total product revenue 19,621 20,628 45,285 38,838 Service and other revenue 5,436 4,588 10,322 9,294 Total revenue $ 25,057 $ 25,216 $ 55,607 $ 48,132

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Summary of Financial Assets Measured at Fair Value on Recurring Basis by Level within Fair Value Hierarchy	The following tables summarize the Company’s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): June 30, 2022 Valuation Amortized Gross Gross Aggregate Assets: Cash equivalents: Money market funds Level 1 $ 31,353 $ — $ — $ 31,353 Short-term investments: U.S. Treasury securities Level 1 76,950 — ( 518 ) 76,432 Corporate debt Level 2 78,645 — ( 437 ) 78,208 Commercial paper Level 2 31,925 — — 31,925 Total cash equivalents and $ 218,873 $ — $ ( 955 ) $ 217,918 December 31, 2021 Valuation Amortized Gross Gross Aggregate Assets: Cash equivalents: Money market funds Level 1 $ 60,844 $ — $ — $ 60,844 Short-term investments: U.S. Treasury securities Level 1 18,064 — ( 60 ) 18,004 Corporate debt Level 2 124,178 2 ( 125 ) 124,055 Commercial paper Level 2 15,081 — — 15,081 Total cash equivalents and $ 218,167 $ 2 $ ( 185 ) $ 217,984

Balance Sheet Components (Table

Balance Sheet Components (Tables)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule Of Cash And Cash Equivalents And Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash that sum to the total of the amounts shown in the accompanying condensed statements of cash flows (in thousands): June 30, 2022 2021 Cash and cash equivalents $ 75,497 $ 274,274 Restricted cash 33,311 33,311 Total cash, cash equivalents and restricted cash $ 108,808 $ 307,585
Schedule of Inventories	Inventories consist of the following (in thousands): June 30, December 31, 2022 2021 Raw materials $ 20,731 $ 18,114 Work in process 9,434 6,054 Finished goods 23,524 15,017 Total inventories $ 53,689 $ 39,185
Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following (in thousands): June 30, December 31, 2022 2021 Accrued inventory $ 9,904 $ 4,808 Accrued research and development expenses 1,113 574 Accrued professional services 1,745 1,269 Accrued rebate 3,737 3,121 Other 6,762 4,017 Total accrued expenses and other current liabilities $ 23,261 $ 13,789

Term Loan (Tables)

Term Loan (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of Term Loan	Term loan consists of the following (in thousands): June 30, December 31, 2022 2021 Principal of term loan $ 30,000 $ 30,000 Unamortized debt discount ( 194 ) ( 238 ) Term loan, current and noncurrent 29,806 29,762 Less: term loan, current ( 1,000 ) — Total term loan, noncurrent $ 28,806 $ 29,762

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Stock-based Compensation Expense	The following table sets forth stock-based compensation expense included in the accompanying condensed statements of operations (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Cost of revenue $ 190 $ 62 $ 283 $ 137 Research and development 1,808 643 2,966 1,808 Sales and marketing 2,864 1,052 4,570 2,794 General and administrative 2,552 2,180 4,601 5,050 Total stock-based compensation expense $ 7,414 $ 3,937 $ 12,420 $ 9,789

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Schedule of Outstanding Potentially Dilutive Shares were Excluded from Calculation of Diluted Net Loss Per Share	The following outstanding potentially dilutive shares were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Stock options to purchase common stock 2,900 4,653 2,900 4,653 Restricted stock units 1,513 473 1,513 473 Performance stock units 31 — 31 — Shares committed under ESPP 101 27 101 27 Warrant to purchase common stock 63 63 63 63 Total 4,608 5,216 4,608 5,216

Description of Business - Addit

Description of Business - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Description Of Business [Line Items]
Proceeds from issuance of common stock upon follow-on public offering, net of issuance costs					$ 0	$ 149,085
Net loss	$ 43,839	$ 36,892	$ 30,208	$ 30,025	80,731	$ 60,233
Accumulated deficit	(706,725)				(706,725)		$ (625,994)
Cash, cash equivalents and short-term investments	262,100				262,100
Restricted cash	33,311				33,311		$ 33,311
Cash, cash equivalents, restricted cash and short-term investments	$ 295,400				$ 295,400

Revenue and Deferred Revenue -

Revenue and Deferred Revenue - Summary of Revenue by Source (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation Of Revenue [Line Items]
Revenue	$ 25,057	$ 25,216	$ 55,607	$ 48,132
Consoles Product
Disaggregation Of Revenue [Line Items]
Revenue	13,228	16,857	31,279	31,623
Consumables Product
Disaggregation Of Revenue [Line Items]
Revenue	6,393	3,771	14,006	7,215
Product Revenue
Disaggregation Of Revenue [Line Items]
Revenue	19,621	20,628	45,285	38,838
Service and Other Revenue
Disaggregation Of Revenue [Line Items]
Revenue	$ 5,436	$ 4,588	$ 10,322	$ 9,294

Revenue and Deferred Revenue _2

Revenue and Deferred Revenue - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Remaining performance obligations	$ 8		$ 8
Revenue recognized	1.7		4.2
Consoles Product | Operating Lease Arrangements
Revenue from operating lease arrangements	$ 0.7	$ 1.3	$ 1.4	$ 2.6

Revenue and Deferred Revenue _3

Revenue and Deferred Revenue - Additional Information (Detail) 1 $ in Millions	Jun. 30, 2022 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-10-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-04-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue performance obligation	$ 7.8
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-10-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue performance obligation	$ 0.2

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Detail) - Fair Value, Recurring - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Costs	$ 218,873	$ 218,167
Gross Unrealized Holding Gains		2
Gross Unrealized Holding Losses	(955)	(185)
Aggregate Fair Value	217,918	217,984
Level 1 | Cash equivalents | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Costs	31,353	60,844
Aggregate Fair Value	31,353	60,844
Level 1 | Short-term investments | U.S. Treasury securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Costs	76,950	18,064
Gross Unrealized Holding Losses	(518)	(60)
Aggregate Fair Value	76,432	18,004
Level 2 | Short-term investments | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Costs	31,925	15,081
Aggregate Fair Value	31,925	15,081
Level 2 | Short-term investments | Corporate debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Costs	78,645	124,178
Gross Unrealized Holding Gains		2
Gross Unrealized Holding Losses	(437)	(125)
Aggregate Fair Value	$ 78,208	$ 124,055

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail)	3 Months Ended	6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)
Fair Value Disclosures [Abstract]
Remaining contractual maturities for available-for-sale securities		one month to thirteen months
Securities in unrealized loss position for more than 12 months	$ 18,000,000	$ 18,000,000
Unrealized Losses Caused By Change In Market Interest Rates		89,000
Other-than-temporary impairment losses related to investments	$ 0	$ 0

Balance Sheet Components (Addit

Balance Sheet Components (Additional Information) (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021
Balance Sheet Components
Restricted cash balance	$ 33,311	$ 33,300	$ 33,311

Balance Sheet Components - Sche

Balance Sheet Components - Schedule Of Cash And Cash Equivalents And Restricted Cash (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 75,497	$ 182,348	$ 274,274
Restricted cash	33,311	$ 33,300	33,311
Total cash, cash equivalents and restricted cash	$ 108,808		$ 307,585

Balance Sheet Components - Sc_2

Balance Sheet Components - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 20,731	$ 18,114
Work in process	9,434	6,054
Finished goods	23,524	15,017
Total inventories	$ 53,689	$ 39,185

Balance Sheet Components - Accr

Balance Sheet Components - Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued inventory	$ 9,904	$ 4,808
Accrued research and development expenses	1,113	574
Accrued professional services	1,745	1,269
Accrued rebate	3,737	3,121
Other	6,762	4,017
Total accrued expenses and other current liabilities	$ 23,261	$ 13,789

Term Loan - Schedule of Term Lo

Term Loan - Schedule of Term Loan (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Principal of term loan	$ 30,000	$ 30,000
Unamortized debt discount	(194)	(238)
Term loan, current and noncurrent	29,806	29,762
Less: term loan, current	(1,000)	0
Total term loan, noncurrent	$ 28,806	$ 29,762

Term Loan - Additional Informat

Term Loan - Additional Information (Detail) - USD ($) $ in Thousands		6 Months Ended
	Jul. 02, 2020	Jun. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Principal of term loan		$ 30,000	$ 30,000
Debt discount on Perceptive Term Loan		$ 194	$ 238
SVB Term Loan
Debt Instrument [Line Items]
Principal of term loan	$ 30,000
Loan maturity date	Nov. 01, 2025
Description of payment terms		Payments under the SVB Term Loan are for interest only through May 2023, and then 30 monthly principal and interest payments from June 2023 until maturity.
Debt instrument interest only payments end date	2023-05
Debt instrument principal repayment period	30 months
Debt interest rate		5.25%
SVB Term Loan | Prime Rate
Debt Instrument [Line Items]
Basis spread on variable rate	0.50%

Equity Incentive Plans - Additi

Equity Incentive Plans - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Feb. 28, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Jan. 01, 2022
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Earned units vesting percentage				50%
Stock-based compensation expense		$ 7,414	$ 3,937	$ 12,420	$ 9,789
Stock Option
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock options, description				25% quarterly over the course of the second year, and 50% quarterly over the course of the third year, or (ii) 33% on the first anniversary of the original vesting date, with the balance vesting quarterly over the remaining two years. Prior to February 2022, RSUs with a service-based vesting condition granted to a grantee generally vest at a rate of 25% on the first anniversary of the original vesting date
RSUs
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Percentage of restricted stock issued to CEO				50%
Percentage of restricted stock issued to other executive officers				80%
Earned units vesting percentage	25%
PSUs
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Percentage of restricted stock issued to CEO				50%
Percentage of restricted stock issued to other executive officers				20%
2020 Equity Incentive Plan
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Common stock shares reserved for issuance		5,022,000		5,022,000		1,890,000
Employees Share Purchase Plan (ESPP)
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Common stock shares reserved for issuance		1,416,000		1,416,000		472,000

Equity Incentive Plans - Summar

Equity Incentive Plans - Summary of Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Equity Incentive Plan [Line Items]
Cumulative stock-based compensation	$ 7,414	$ 3,937	$ 12,420	$ 9,789
Cost of Revenue
Equity Incentive Plan [Line Items]
Cumulative stock-based compensation	190	62	283	137
Research and Development
Equity Incentive Plan [Line Items]
Cumulative stock-based compensation	1,808	643	2,966	1,808
Sales and Marketing
Equity Incentive Plan [Line Items]
Cumulative stock-based compensation	2,864	1,052	4,570	2,794
General and Administrative
Equity Incentive Plan [Line Items]
Cumulative stock-based compensation	$ 2,552	$ 2,180	$ 4,601	$ 5,050

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Outstanding Potentially Dilutive Shares were Excluded from Calculation of Diluted Net Loss Per Share (Detail) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from calculation of diluted net loss per share	4,608	5,216	4,608	5,216
Stock Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from calculation of diluted net loss per share	2,900	4,653	2,900	4,653
Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from calculation of diluted net loss per share	1,513	473	1,513	473
Warrant to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from calculation of diluted net loss per share	63	63	63	63
Shares Committed under ESPP
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from calculation of diluted net loss per share	101	27	101	27
Performance Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from calculation of diluted net loss per share	31		31